Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 (CB1) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects.

[1][2] It was developed by Merck & Co.

In October 2008, Merck stopped its phase III clinical trials with the drug due to high level of central nervous system side effects, mainly depression and anxiety.

[3][4][5][6] This cannabinoid related article is a stub.

You can help Wikipedia by expanding it.